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FOLLOWING the researches of Jacobson and his colleagues (Jacobson et al.,
1948, 1949a, 1949b, 1950) Lorenz showed that the intravenous infusion of viable
isologous marrow cells prevented the death of lethally irradiated mice and guinea
pigs (Lorenz et al., 1951). Protection against lethal doses of some radiomimetic
drugs has also been effected in this way (Weston et al., 1957 ; Sartorelli and
LePage, 1957; Talbot and Elson, 1958; Tran Ba Loc et al., 1958; Kirschbaum,
1958; Dunjic and Maisin, 1960). This work was extended by the Harwell Group
(Barnes et al., 1956) when they showed that mice could be cured of leukaemia by
a single large dose of radiation followed by marrow infusion. Many reports of
this method of treatment, following chemotherapy as well as radiotherapy, sub-
sequently appeared. (Trentin, 1957; Sartorelli and LePage, 1957; Barnes and
Loutit, 1957; Hewitt and Wilson, 1958, 1959a; Mathe and Bernard, 1958,
1959 ; de Vries and Vos, 1958 ; Maddock and Djerassi, 1958 ; Uphoff, 1958 ;
Schwartz, 1958, 1959; Cole and Ellis, 1958). This work has shown that in spite
of its early promise the method does not permit the eradication of established
malignant disease, but when the tumour is relatively slowly growing useful
remissions may be obtained. In extending this work to man, the first essential is
to decide how many marrow cells it is necessary to infuse in order to secure
recovery. Because of its greater simplicity and practical importance the auto-
logus (or isologous) situation will be considered first. Since there are good
grounds for supposing that all mammalian cells have remarkably similar radio-
sensitivities (vide infra) the proportion of the total marrow which is effective in
experimental animals should be effective in man.
The effective dose of marrow cells
The various methods of assessing total marrow cellularity in animals and
man are discussed in the appendix, and the value for each of the relevant species
is given. In Table I the total marrow cellularity of these animals is compared
with the minimum dose of marrow cells which will regularly protect all of the
animals against LD100 irradiation. Such an infusion amounts to between 041
and 0 7 per cent of the total cellularity. When this is applied to man it is found
that the necessary quantity of bone marrow (0.8-5*6 x 109 cells for a 70 kg. man)
can be obtained and stored by techniques currently in use (Pegg and Kemp, 1960).
Nevertheless it has been argued (Lajtha, 1959, 1960a) that the quantity ofmar-
row injected in human work is so small in comparison with the marrow remaining
after the irradiation that the infusion would not be expected to be of benefit.QUANTITATIVE STUDY OF MARROW GRAFTING
TABLE I.--The Minimum Doses of Jsologous or Autologous Marrow (Cells required
to Protect Animals Exposed to Lethal Irradiation
Effective
marrow dose
Total body - . Isologous Reference to
Body inarrow 0/ total or mnarrow
Species weight (cells) Cells marrow autologous p)rotection data
Mlouse . . 24grmi. 6-8x 108. 1Ox 106 01 . I van Bekkum and
Vos, 1957.
Rat . 200 . . 6-Ox IO9 4- x 10 0- 7 I van Bekkum and
Vos, 1957.
Guinea-pig 600 ,. 16- . Ox 109 8x108* 1.1* I . Congdon, 1957.
Congdon, 1961,
personal com-
mnunication.
Dog 13 kg. 2-8x101l . 2-Ox 1O0 0-7 . A Alpen and Baum,
1958.
Rhesus monkev 4 ,, . 9-6x1010 . 4-0x108 0-4 . A Crouch etal., 1961.
* The mininumi dose was nIot determined.
This view is based on the application of radiation survival curve data to human
total marrow cellularity. Although the results of such calculations can hardly
affect the validity of the experimental observations referred to in the previous
paragraph they have considerable theoretical interest and it will be instructive
to apply this analysis to those experimental animals for which adequate radio-
biological data is available.
Method of analysis
The total marrow cellularity of the relevant animals has already been referred
to. A discussion ofradiation survival curve data follows and an apriori examina-
tion of its applicability to the present problem is made. Following this, three
sets of calculations are presented ; the first is Lajtha's comparison between the
amount of marrow surviving in the lethally irradiated animal and the number of
marrow cells infused in a typical experiment. In the second set of calculations
the amount of marrow remaining after midlethal irradiation is compared with the
sum of the surviving and injected marrow cells in lethally irradiated animals
protected by bone marrow. The final calculation concerns the reduction in
radiation dose which would be expected to increase the number of marrow cells
surviving an LVI 100 dose by an amount equal to that contained in the marrow
infusion.
Radiation survival curves
Puck and Marcus (1956) showed that when HeLa cells are irradiated in vitro,
the surviving fraction is a logarithmic function of the radiation dose, survival
being used in the sense ofunimpaired reproductive integrity (Gray, 1959). Radio-
sensitivity is best expressed as the Do value (Lea and Gray, 1956); this is the
dose which reduces the surviving fraction to e-1 or about 37 per cent, and was
found to be 140 rads in Puck's system (Morkovin and Feldman, 1959, 1960;
Hewitt and Wilson, 1960). In a later paper (Puck et al., 1957) it was shown that
a wide variety of cells derived from both normal and malignant human tissue
exhibited remarkably similar survival curves. Hewitt and Wilson (1959b)
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described a strikingly similar curve for murine leukaemia cells irradiated and
assayed in vivo (Do = 160 r 60Co) and Berry and Andrews (1961) have recently
used a similar method to obtain a Do of 160 r 3 MeV X-rays for an ascitic leukae-
mia of DBA mice.
Thus, the radiosensitivity of many cell types of different mammalian species
has been found to be almost identical. Puck (1959) made the interesting observa-
tion that the Do for yeast, avian and mammalian cells is a function of the cellular
DNA content and this has also been suggested by radiosensitivity measurements
in twenty-four plant species (Sparrow and Miksch, 1961). Since the DNA content
of mammalian cells is remarkably constant irrespective of species and tissue
(5-0-6'0 ,au,g. per cell, Vendrely, 1955) there is now both experimental and theo-
retical evidence suggesting that the radiosensitivity of all cells of all mammals is
very similar. There is, therefore, every justification for applying the standard
survival curve to the bone marrow of all the experimental mammals and man.
In doing so, the Do value of Morkovin and Feldman (140 rads) will be used since
this avoids any correction for relative biological efficiency in the experiments
which will be quoted; the calculations will be made on the total bone marrow
numbers with the assumption that the stem cells form the same proportion of
the infused marrow as they do of the bone marrow in situ.
Results of the Analysis
Table II sets out a comparison between the amount of marrow calculated to
retain the capacity for indefinite multiplication after an LD100 dose of radiation
and the number of marrow cells infused in the series of successful protection ex-
periments cited in Table I. The marrow cells calculated to survive the radiation
TABLE II. (oCmparison of the Amount of Marrow Calculated to Survive Lethal
Irradiation and the Effective Dose of Infused Marrow
Marrow cells
LDIOO surviving Effective
Animal (r) the radiation marrow dose
Mouse. 6.75 16-2X 106 1- 0 X 106
Rat . . 650 12- 0 x 107 4-0x107
Guinea-pig . . . 550* 6-4 x 108 . 1-8x108
Dog 600 81 x 109 2Ox 109
Rhesus monkey . 650 . 19-2 x 108 . 4 0 x 108
* Congdoni et al., 1952.
outnumber the infused marrow by between 3-5 to 1 and 16-2 to 1 in the different
species, which is just as unimpressive as Lajtha found to be the case with man.
In spite of this, the mortality was reduced from 100 per cent to nil. It seems,
therefore, that the numerical comparison is misleading.
Table III sets out a comparison between the sum of the surviving and infused
marrow cells in an LD100 experiment and the amount of marrow calculated to
remain intact after LD50 irradiation. The surprising fact emerges that in each
case there appear to be more marrow cells in LD50 irradiated animals (half of
which die) than there are in lethally irradiated, marrow protected animals (not
one in twentv of which die).
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TABLE III.-Comparison of the Amount of Marrow Calculated to Survive LD50
Irradiation and the Amount ofMarrow Present in Lethally Irradiated, Marrow-
protected Animals
Sum of cells
Marrow cells surviving the
LD50 surviving LD10o and
Animal (r) the LD50 infused cells
Mouse . . . 550 . 38-0x106 . 17-2 X 106
Rat . . . 575 21-0x107 . 16-0 x 107
Guinea-pig. . 400 . 19 4 x 108 8- 2x 108
Dog . . . . 280 76-0 x 109 10 1 x 109
Rhesus monkey . . 528* . 46-0 x 108 . 23-2 x 108
* Cronkite and Brecher, 1955.
TABLE IV.-Calculated Reduction in the LD100 Irradiation Dose which should be
Equivalent to an Effective Marrow Infusion
Radiation dose
to produce Reduction of
Sum of cells this cell radiation dose
surviving the survival without equivalent to the
LD1oo and marrow infusion LD1" marrow infusion
Animal infused cells (r) (r) (r)
Mouse . . 17.2 x 106 . 668 . 675 . 8
Rat . . . 16-0 x 107 . 610 . 650 . 40
Guinea-pig . 8- 2 x 108 . 520 . 550 . 30
Dog . 101 x 109 . 570 . 600 . 30
Rhesus monkey 23.2 x 108 . 625 . 650 . 25
Table IV provides an even more striking illustration of the inappropriateness
ofthis analysis. Here, the sum ofthe surviving and injected cells in the protected
lethally irradiated animals is applied to the radiation survival curve in order
to derive the radiation dose which would have been expected to result in the
survival of this number of marrow cells without marrow infusion. It is found
that the reduction in radiation dose equivalent to an effective marrow infusion
is between 8 and 40 r; such a reduction would make veray little difference to the
survival of the irradiated animals.
From all this it is quite clear that the cells calculated to survive the radiation
dose are not numerically comparable with the freshly infused cells. It seems that
there are four possible reasons for this, any or all of which may operate.
1. The bone marrow cells may have a greater intrinsic radiosensitivity than
all other tested cells.
2. The radiation dose absorbed by the bone marrow may be higher than that
for the remaining tissues.
3. The growth rate of the cells surviving the radiation may be reduced during
the crucial recovery phase.
4. A humoral factor may contribute significantly to radiation recovery after
marrow injection.
These factors will now be considered in turn.
Radiosensitivity of bone marrow
It was pointed out in a previous section that there is every reason to believe
that bone marrow cells have the same intrinsic radiosensitivity as other cells.
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Recently, Till and McCullock (1961) have devised an ingenious technique to
measure the radiosensitivity of mouse bone marrow. The method depends on
the ability of marrow cells injected into irradiated recipients to form detectable
splenic nodules in a fixed time; consequently it is dependent on alterations of
growth rate as well as survival of reproductive capacity. The Do obtained
(115 r) is slightly lower than that obtained for other cells, but this may very well
be due to a temporary effect ofradiation on growth rate (vide infra). In any case,
the discrepancy is not great and although the possibility of increased radio-
sensitivity ofbone marrow cannot be rejected it seems unlikely to be the principal
cause of the effects noted here.
Absorbed radiation dose
It has been shown that the absorbed dose in irradiated tissues is greater when
the effective atomic number is high (Spiers, 1946) and that at the boundary of a
tissue such as bone, secondary electron emission delivers an increased dose to the
adjacent soft tissue (Spiers, 1949, 1951; Wilson, 1950; Woodard and Spiers,
1953). This effect is considerable up to 80 /a from a bone surface when 200 kv
X-rays are used, as they were in all the experiments quoted here, and wouldthere-
fore deliver a greater dose to the bone marrow than the whole-body dose. This
could be highly significant if some of the effective marrow cells are intimately
associated with the bone surface, where the absorbed dose may be 2-5 times as
great as in distant soft tissue. The success of Lorenz and Congdon (1954) in
providing radiation protection by the implantation ofwashed bone chips suggests
that this may be so. Direct evidence favouring a high absorbed dose for bone
marrow was providedby Belcher et al. (1958) whenthey showed that after uniform
sublethal irradiation of rats splenic erythropoiesis recovered before the bone
marrow. It is concluded that this phenomenon accounts at least in part for the
findings presented above.
The growth rate of radiation survivors
Puck and Marcus (1956) in their paper describing the radiation survival curve
noted that cells surviving radiation grew more slowly thanunirradiated cells. This
was not due simply to a delay in the resumption ofmitosis, for although the effect
was certainly most striking in the period immediately following irradiation, it
was still apparent as long as 10 days afterwards. The earlier work of Reid and
Gifford (1952) also shows this effect; mouse fibroblasts were found to take 16
days to recover their original growth rate after 500 r. Kohn and Fogh (1959)
showed that human amnion cells in tissue culture were still growing slowly 10
days after 600 r. All this does not imply that radiation survivors have a per-
manently depressed growth rate, but if a similar phenomenon applies to bone
marrow cells it does mean that they are dividing abnormally slowly during the
crucial regenerative phase following radiation.
A humoralfactor
The evidence is quite overwhelming that bone marrow infusions protect by
cellular repopulation (see, for example, Barnes and Loutit, 1954, 1956; Ford
et al., 1956; Vos et al., 1956), but there remains some evidence suggesting that a
404QUANTITATIVE STUDY OF MARROW GRAFTING
humoral factor may play a small part (Ellinger, 1956). It seems unlikely, how-
ever, that a humoral agent would play any more than a very small part in radia-
tion protection. Analysis of marrow infusion experiments in terms of viable
marrow cells alone is therefore justified.
It is concluded from these considerations, that when bone marrow cells are
irradiated in situ with 200 kv X-rays, they probably exhibit a survival curve which
is steeper than the standard curve because of secondary electron emission from
the bone surfaces. In addition, the cells surviving irradiation grow more slowly
during the crucial recovery phase. These two factors combine to make the
surviving cells calculated by the standard curve quantitatively less effective
than the infused marrow and account for the anomalies in Lajtha's method of
analysis. There is no reason to suppose that the proportion of the total
marrow which forms an effective infusion in experimental animals would not do
so in man.
Protection by homologous bone marrow infusion
Quantitative data is available for four species (Table V) although the effective
marrow dose given for the dog may may not be a minimum dose. It is seen that
between 1P2 and 1 7 per cent of the total marrow is required for radiation protec-
TABLE V. The Minimum Doses of Homologous Marrow Cells to Protect Animals
Exposed to Lethal Irradiation
Effective marrow dose
Radiation dose --- -
at least LD100 % total
Animiial (r) Cells rnarrow Refeireince
Mouse 675 1-0 x 10 1- van Bekkunm et al., 1956.
Rat . 675-700 1-0x 108 1 7 Fishler et al., 1954.
Dog 800-1200 4-3 x 109* 1- 2 . Thomas et al., 1959.
Rhesus imionkey 600-865 12 0 x108 1- 2 Crouch et al., 1961.
* Mean of 11 successful transplants.
tioin. This would amount to between 9 and 13 X 109 cells for a 70 kg. man and
proportionately less for children. The quantities required for children can easily
be obtained by standard techniques, and although the amount required for adults
approaches the upper limit of yields usually obtained, there is no doubt that
such quantities can be obtained when the need arises.
However, it is most important that the two principal hazards ofthis procedure
should be reckoned with: the first is the mid-lethal dose effect (van Bekkum
and Vos, 1957) whereby the survival rate is decreased by homologous marrow
infusion at around the LD 50, and the second is the danger ofproducing secondary
disease (Mathe et al., 1960). Clearly, in cases of accidental radiation exposure
these possibilities must be balanced against the risk to the patient of withholding
the treatment, but it seems to be beyond doubt that the deliberate production of
bone marrow aplasia in order to infuse homologous bone marrow is not justified
at the present time. If homologous marrow infusions are to be carried out the
greatest possible yield of cells should be obtained and blood contamination kept
to a minimum (Goodman and Congdon, 1961).
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Bone marrow grafting in chemotherapy
Quantitative data concerning isolgous marrow infusions are shown in Table
VI. No clearly established example appears to have been described of successful
marrow grafting following chemotherapy of an animal. It is at once obvious
that the amount of isologous marrow required was greater than that used in
radiation protection although the survival rate was lower. It also seems to be
quite clear that better results were obtained after myeleran than after nitrogen
mustard. The following explanation of these observations is offered.
Haematological recovery after radiation is much slower than it is after alkylat-
ing agents, and Elson et al. (1958) have shown that among alkylating agents
nitrogen mustards permit much more rapid recovery than myeleran. It takes
1-2 weeks for bone marrow aplasia to kill, but by this time recovery is well under
way in the animal treated with moderate amounts ofnitrogen mustard, and even
with myeleran it has started. Bone marrow infusions will therefore make rela-
tively little difference to the outcome; consequently, it is necessary to give
relatively larger doses ofthese drugs in order to demonstrate any benefit from the
marrow infusion. However, larger doses produce toxic effects on other systems
which kill the animal more rapidly than bone marrow aplasia and are not bene-
fitted by marrow infusion.
These findings carry important implications for clinical work. In the
first place, it is clearly desirable to obtain as much marrow as possible for auto-
logous infusion. Secondly, one is not likely to obtain the best results by increasing
the dose of an agent producing a transient effect on the bone marrow. Rather,
one should select drugs like myeleran and mannomustine which are known to
produce prolonged haemopoietic depression.
Therapeutic measures other than bone marrow infusion in lethally irradiated animals
Since the principal hazards of bone marrow hypoplasia are infection and hae-
morrhage, measures designed to limit these complications should promote recovery
of the irradiated mammal. Also, if it were possible to stimulate the surviving
bone marrow this should increase survival. These three possible therapeutic
measures will now be considered.
1. Control ofinfection.-It has been conclusively shown that the most frequent
cause of death in irradiated mice dying with the bone marrow syndrome is in-
fection (Miller et al., 1950a, 1951). Antibiotics reduce mortality among mice
receiving 450 r (Miller et al., 1950b), but in rats irradiated to this dose (Lambert
et al., 1950) and in mice receiving more than 600 r there is little or no benefit
(Osborne et al., 1952). Similar results were obtained in dogs (Allen et al., 1951)
and in rabbits (Wilson et al., 1959). Smith et al. (1955) compared marrow cell
infusions with streptomycin in the treatment of irradiated hamsters and it was
found that whereas the antibiotic raised the LD50 by 100 r marrow infusion raised
it by 380 r. Sterile nursing is not practicable with small animals, but has been
advocated in the treatment of human subjects exposed to whole body irradiation
(Tubiana et al., 1961). This measure should provide some protection against
the hospital pathogens, but since the organisms which usually produce fatal
septicaemia in irradiated animals are bowel commensals, barrier nursing is unlikely
to improve survival. The chemotherapeutic methods available for sterilising
the bowel carry a very considerable risk of producing overwhelming infection by
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Candida albicans and the development of antibiotic resistant bacterial strains.
The systemic use ofbroad spectrum antibiotics is also capable ofcausing dissemin-
ated moniliasis, which is frequently fatal in the leukopenic patient.
2. Control ofhaemorrhage.-The value of fresh blood in the control of haemor-
rhage in irradiated dogs has been studied by Allen et al. (1951, 1952). It was
found that even when blood was given in large amounts thrice weekly it failed
to produce haemostasis or increase survival unless antibiotics were also given;
then mortality fell from 100 to 80 per cent. Cronkite and Brecher (1952) were
able to improve haemostasis in irradiated dogs with platelet infusions but
survival did not increase: Soybean phosphatide was found to be an equally
effective haemostatic (White et al., 1953). Jackson et at. (1958) controlled the
bleeding in dogs with fresh platelets but found that lyophilised platelets were
ineffective. This was confirmed in rats by Fliedner et al. (1958). It is clear that
fresh platelet infusions can arrest haemorrhage in irradiated recipients, but unless
other measures are also used there is not even a modest improvement in survival.
3. Acceleration of marrow regeneration.-Lajtha (1960b) has suggested that
measures to accelerate marrow regeneration may be useful in radiation protection.
Unfortunately the evidence available shows only very slight benefit from such
measures. Patt et al. (1955) stated in a brief communication that injection of
rabbitanti-dogserum into irradiated dogs increased their survivalto anunspecified
degree, while Kelly and Jones (1953) reported that injections of liver or embryo
homogenates increased the survival of irradiated mice from 8 to 24 per cent; an
even smaller benefit was obtained by Forssburg et al. (1960). Stohlmann's
group (Stohlmann et al., 1955, 1956) have studied the stimulation ofbone marrow
after 150-200 r, but this is not directly applicable to the present problem.
Venesection would be expected to provide some bone marrow stimultion, but
is unlikely to be acceptable in clinical work since the patients are usually
already anaemic.
4. Conclulsionsfor human work.-None ofthese methods possesses the potency
of autologous or isologous marrow infusion, but many of them find a place in
conjunction with marrow infusion. The hospitalised patient should be sterile
nursedto avoid contact with the " hospitalpathogens " and, even more important,
the attendants shouldbethoroughly screenedtoeliminate any carriers ofdangerous
pathogens. Antibiotics should be reserved for definite infections, which should be
treated promptly and thoroughly. Fresh platelet transfusions should be given
for thrombocytopenic haemorrhages, but ifblood is required it shouldbe irradiated
to eliminate immunologically competent cells (Goodman and Congdon, 1961).
SUMMARY AND CONCLUSIONS
1. Radiation survival curve data and total bone marrow cellularity measure-
ments in experimental animals and man are reviewed.
2. On the basis of total bone marrow cellularity and the minimum effective
marrow infusion in animal experiments it is concluded that a 70 kg. man would
require 0*7-5*2 x 109 autologous marrow cells or 9-13 x 109 homologous marrow
cells after lethal whole-body irradiation. Bone marrow protection is far less
effective after lethal doses of radiomimetic chemotherapeutic agents.
3. When the numbers of marrow cells calculated to survive various doses of
whole-body irradiation are calculated and compared with the amount of marrow
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infused in successful isologous marrow grafting experiments, it is found that
numerical comparison gives unacceptable results ; reasons for this anomaly are
suggested which avoid the proposition that marrow cells have an intrinsic radio-
sensitivity different from that of other somatic cells.
4. The practical care of the patient who has received large doses of wholebodv
irradiation or radiomimetic chemotherapy is considered. The potency of auto-
logous marrow infusion and the dangers of homologous marrow infusion are
emphasised and the place of antibiotics, platelet and whole blood treatment is
discussed.
APPENDIX
Total bone marrow cellularity
It is proposed to review here the various estimates of total bone marrow
cellularity which have been made in those animals for which radiobiological data
are available, and in man. These include the mouse, the rat, the guinea pig, the
rhesus monkey and the dog. Three techniques have been used; these may be
designated the anatomical, erythrokinetic and radioiron methods. In the case
of each animal the most reliable estimate will be emphasised and the estimates
for the different species compared.
The anatomical method
In this technique the unit cellularity of bone marrow is multiplied by the
estimated total marrow volume. Experiments have been made to estimate the
total marrow cellularity of man and of the CBA mouse using this principle.
1. Man.-As much marrow as possible was collected from each of 12 human
ribs excised during thoracotomies; an average of 1 2 x 109 cells was obtained
SD 0-7 x 109 cells). This is taken to be the marrow content of one rib. The
volume in which this marrow was contained has been estimated from Woodard
and Holodny's breakdown of Mechanik's data for human total marrow volume
(Woodard and Holodny, 1960; Mechanik, 1926); the result is 9-3 ml. which
results in a rib marrow cellularity of 1-29 x 106 cells/cu. mm. Custer (1932)
has showni that the rib marrow of adults is only about 30 per cent as cellular as
the marrow contained in other sites. If allowance is made for this, Mechanik's
estimate oftotal erythropoietic marrow volume (1500 ml., Mechanik, 1926) makes
it possible to calculate the total marrow cellularity. The result is 8 1 x 109
cells/kg.
2. The mouse. The femora of 4 freshly killed 25 g. CBA mice were gently
excised and the epiphyses removed cleanly with a new razor blade. The marrow
cells were washed out of each shaft using a very fine Pasteur pipette and TC 199)
with 2 5 per cent polyvinylpyrrolidone. The cell suspensions were diluted to
exactly 1l0 ml. and cell counts made in a haemocytometer. Between 5 4 anld
8X4 x 106 cells were obtained from each femoral shaft.
The femoral shaft was found to be horn shaped with an eliptical cross sectioni.
Its volume was found by the following procedure: the maximum and minimum
radii were measured at each end using a microscope micrometer and the length
was measured with an engineer's screw micrometer; the femur was then ground
down from one end using a dental carborundum wheel and radii were measured
at three intermediate points; the area of each cross section was calculated from
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the formula A -7 r1 r9, and the volume was measured as the area enclosed bv
a graph of cross sectional area against length. From these data the unit cellu-
larity of CBA mouse marrow was found to be 2 41 x 106 cells/cu. mm. (SD 0-20
x 106 cells/cu. mm.).
The total marrow volume was assumed to be 1 65 per cent of the whole body
volume and the specific gravity 1P0; the total marrow cellularity was 39-8 x 106
cells/kg. (SD 3.3 x 106 cells/kg.).
3. Published data. The unit cellularity of rat marrow has been estimated
by a histological technique (Kindred, 1942) and by the more accurate method of
counting cells in suspensions made from known weights or volumes of marrow
(Fruhman and Gordon, 1953; Meineke and Crafts, 1956; Awaya et al., 1960).
The two estimates for Wistar rats agree well (1.75 and 1 81 x 106/cu. mm.).
Similar techniques have been used to measure the cellularity of marrow removed
from the dog (Rekers and Coulter, 1948), the guinea pig (Yoffey, 1961 ; Fand and
Gordon, 1957) and the C3H mouse (Vogel, 1961). Vogel's figure of 1 8 x 106
cells per cu. mm. is rather lower than my own result for CBA mice.
Total marrow volume was first measured by Mechanik (1926) who macerated
human bones, but the agar impregnation technique of Nye (1931) was a con-
siderable improvement. He filled the dried marrow-containing bones of the
rabbit with agar and noted their increase in volume; a value of 1-7 per cent ofthe
body weight was obtained. The same technique was used by Fairman and Whip-
ple (1933) to determine the total marrow volume of adult mongrel dogs; using
the additional data of Oehlbeck, Robscheit-Robbins and Whipple (1932) an
erythropoietic marrow volume of 1 65 per cent of the body weight is obtained.
A very painstaking study using an improved agar technique led Hudson (1958)
to estimate the total haemopoietic marrow volume of the guinea pig at 1 56 per
cent of the body weight. The first estimate of albino rat marrow volume was
3 0 per cent of the body weight (Fairman and Corner, 1934), but more recent
estimates have both been 1-65 per cent (Hashimoto, 1953 ; Watanabe, 1955).
It is interesting to note that the marrow volume of all these animals falls in the
very narrow range of 1 56-1-7 per cent of body weight. For this reason one is
confident in using the mean (1 65 per cent) in calculating mouse marrow cellularity.
V'ogel's assumption of 2 per cent is probably a little high.
The anatomical method permits the calculation of the total marrow cellularitv
of mouse, rat, guiinea pig, dog and man.
The erythrokinetic method
Kindred (1942) suggested that consideration of red cell production could be
used to calculate total marrow cellularity, but as Patt (1957) pointed out, the
data available for these calculations were not very precise. Osgood (1954)
calculated the total bone marrow cellularity from an assumed red cell production
rate, a normoblast maturation time, the myeloid: erythoid ratio and the ratio
of proliferating to differentiating normoblasts. His result (46 x 109 cells per
kg.) was an over-estimate, because the marrow reticulocyte stage was ignored; if
this is allowed for on the basis that there are two marrow reticulocytes for each
differentiating normoblast (Patt, 1957) the estimate becomes 9-3 x 109 cells per
kg. This is in quite good agreement with Patt's own calculation of 13-4 x 109
cells/kg. which was based on red cell output, mitotic index, the duration of mitosis
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and assumed proportions of marrow reticulocytes, proliferating normoblasts
and proliferating myeloid cells. The principal uncertainty of this method lies
in the assumed duration ofmitosis, although when this method is used to calculate
the marrow cellularity of the rat and the dog some of the other data are not very
well established. It is interesting to note that when the duration of mitosis
is derived from Osgood's revised calculations it is 37 minutes for the myeloid
series and 38 minutes for the erythroid series; Patt's assumption was 45 minutes
for both myeloid and erythroid cells.
The erythrokinetic method has enabled the total marrow cellularity of manl,
the rat and the dog to be calculated. Patt's procedure gives the total of the
ervthroid and mveloid cells: in Table VlII 10 per cent has been added to allow
for other cells.
The radioiron method
Suit (1957) showed that the radioactive iron isotope 59Fe could be used to
measure total marrow cellularity in man. He assumed that when an 59Fe salt
is injected intravenously the amount of 59Fe present in the total bone marrow 24
hr. later is the same as that present in the total red cell mass on the eighth day;
consequently the 59Fe taken up by the marrow can be measured. If a marrow
sample is taken at 24 hr., the ratio of its cell content and 59Fe activity will be the
same as the ratio ofthe total marrow cellularity and the total 59Fe content at 24 hr.
An allowance was made for reticulocyte uptake and the total marrow cellularity
calculated. Suit recognised that some of these assumptions were approximate,
but it seems that the error in assessing the proportion of the 59Fe taken up by
the marrow is considerable, since it has been shown that some ofthe iron originally
cleared to the stores is utilized for haemoglobin synthesis during the eight-day
period (Finch et al., 1949). ]Donohue et al. (1958a and b) used a fixed value of
66 per cent for the proportion of the iron taken up by the bone marrow. This
was derived from direct measurements in animal carcases and seems to be pre-
preferable to Suit's assumption.
Suit measured the total erythroid cellularity in 6 patients with malignant
disease whom he thought " should not be considered normal the mean
value was 16 x 1010 red cell precursors with a considerable range. Assuming a
myeloid-erythroid ratio of 3: 1 and a mean bodv weight of 70 kg. this gives a
total cellularity of 9-1 x 109 cells/kg.
Donohue used the technique to measure the marrow cellularity of man, the
rhesus monkey, the rat and the rabbit, but he made his radioactivity measure-
ments on centrifuged marrow samples and ignored the radioactivity present in
the supernatant. This activity was shown to be derived from the cytoplasm of
cells which were probably included in the nucleated cell counts. Donohue's
results are, therefore, probably overestimates, but since the percentages of the
activity contained in the supernatants are specified it is possible to recalculate
the results to allow for this. Thus, the estimate for man drops from 18 to
13 x 109 cells/kg., for the rhesus monikey from 34 to 24 x 109 cells/kg. and for
the rat from 17 to 12 x 109 cells/kg.
The error introduced by reticulocyte 59Fe uptake is negligible when surgically
excised marrow is used. When the marrow sample has been obtained by needle
puncture its radioactivity must be corrected for the presence of reticulocytes in
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proportion to its red cell content. The inclusion of marrow reticulocytes with a
higher iron uptake introduces an error here (Suit, 1957) but because of the gross
dilution ofmarrow reticulocytes by blood reticulocytes this is less than 1 per cent.
When dealing with aspirated marrow it is of course also necessary to correct the
total nucleated cell count for dilution with peripheral blood leucocytes: this
can be done by simple subtraction. The total marrow cellularity of eight
patients with malignant disease has been measured by this method and a
mean result of 11-5 x 109 cells/kg. obtained. (SD 5-3 x 109).
Harrison (1962) has used the same technique to measure the cellularity of 10
haematologically normal patients and 11 cases of disseminated malignant mela-
noma. In the 10 normal cases marrow was removed both by excision of a rib
and by needle puncture: the agreement obtained between these two methods
confirms the validity of the corrections discussed above. Harrison's mean result
of 10-9 x 109 cells/kg. based on 31 measurements in 21 patients is considered to
be the most reliable estimate of human total marrow cellularity available at this
time.
The 59Fe method has been used to calculate the total marrow cellularity ofthe
rat, the rhesus monkey, the rabbit (not considered here) and man.
DISCUSSION
The various techniques used for the measurement of total marrow cellularity
have given remarkably good agreement. The least satisfactory estimate is that
for the rat, but this may be due at least in part to real variations in cellularity
amongst different strains (Meinecke and Crafts, 1956). Nevertheless, the
anatomical estimates for the Wistar rat are in good agreement: the radiation
experiments quoted used Wistar rats.
It appears that marrow cellularity decreases with increasing body weight,
not only of individual species (Fand and Gordon, 1957), but also between species
(Table VII). Even so, human marrow cellularity expressed in terms of body
weight is surprisingly low. This could be due to longer peripheral survival of the
formed blood cells, but sufficiently reliable data to test this hypothesis are not
available.
I would like to thank Dr. H. B. Hewitt and Mr. J. E. Burns for helpful dis-
cussions and to acknowledge my gratitude to the British Empire Cancer Campaign
for a full time grant.
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